TNFRSF1B and graft versus host disease: On the other hand, it is worth to mention that recent in-silico, ex-vivo (human samples) and in-vivo (mouse model) studies have shown TNFR2-agonists as potential approach for the treatment of autoimmune diseases and graft-versus-host disease (GvHD) [129,130,131].